HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer
出版年份 2019 全文链接
标题
HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer
作者
关键词
-
出版物
Oncogenesis
Volume 8, Issue 9, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-08-20
DOI
10.1038/s41389-019-0158-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma
- (2018) Duo Xu et al. BRITISH JOURNAL OF CANCER
- The Unfolded Protein Response and Cell Fate Control
- (2018) Claudio Hetz et al. MOLECULAR CELL
- Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
- (2018) Julia Boshuizen et al. NATURE MEDICINE
- mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer
- (2018) Shun-Qing Liang et al. ONCOGENE
- Tumor Initiation Capacity and Therapy Resistance Are Differential Features of EMT-Related Subpopulations in the NSCLC Cell Line A549
- (2018) Colin Charles Tièche et al. NEOPLASIA
- Cancer-specific PERK signaling drives invasion and metastasis through CREB3L1
- (2017) Yu-Xiong Feng et al. Nature Communications
- Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy
- (2016) M. Scaltriti et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance
- (2016) M. P. Smith et al. CLINICAL CANCER RESEARCH
- A combinatorial strategy for treating KRAS-mutant lung cancer
- (2016) Eusebio Manchado et al. NATURE
- Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer
- (2016) H. Kitai et al. Cancer Discovery
- A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
- (2015) G. R. Blumenschein et al. ANNALS OF ONCOLOGY
- Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
- (2015) Willy Hugo et al. CELL
- Conversion to stem-cell state in response to microenvironmental cues is regulated by balance between epithelial and mesenchymal features in lung cancer cells
- (2015) Francesca Andriani et al. Molecular Oncology
- Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy
- (2015) R Mandal et al. ONCOGENE
- FunRich: An open access standalone functional enrichment and interaction network analysis tool
- (2015) Mohashin Pathan et al. PROTEOMICS
- Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors
- (2014) Piro Lito et al. CANCER CELL
- Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
- (2014) Ho-June Lee et al. CANCER CELL
- KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
- (2014) Diane D. Shao et al. CELL
- Targeting RAS–ERK signalling in cancer: promises and challenges
- (2014) Ahmed A. Samatar et al. NATURE REVIEWS DRUG DISCOVERY
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3
- (2014) N Robichaud et al. ONCOGENE
- Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
- (2014) Chong Sun et al. Cell Reports
- RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells
- (2014) Simona Lamba et al. Cell Reports
- Molecular Mechanism of 17-Allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL Receptor Tyrosine Kinase Degradation
- (2013) Gnana Prakasam Krishnamoorthy et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2
- (2013) Pallav D Patel et al. Nature Chemical Biology
- Epithelial-to-Mesenchymal Transition Rewires the Molecular Path to PI3K-Dependent Proliferation
- (2013) M. B. Salt et al. Cancer Discovery
- A Comprehensive Survey of Ras Mutations in Cancer
- (2012) I. A. Prior et al. CANCER RESEARCH
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
- (2012) Pasi A Jänne et al. LANCET ONCOLOGY
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
- (2012) Wanjuan Yang et al. NUCLEIC ACIDS RESEARCH
- NCBI GEO: archive for functional genomics data sets—update
- (2012) Tanya Barrett et al. NUCLEIC ACIDS RESEARCH
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells
- (2011) Xiao-Qun Ye et al. INTERNATIONAL JOURNAL OF CANCER
- Harnessing synthetic lethal interactions in anticancer drug discovery
- (2011) Denise A. Chan et al. NATURE REVIEWS DRUG DISCOVERY
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors
- (2010) V. Vaira et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival
- (2009) Anurag Singh et al. CANCER CELL
- Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
- (2009) Michel DuPage et al. Nature Protocols
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started